Skip to main content
Farmacosmo logo

Farmacosmo — Investor Relations & Filings

Ticker · ZJ1 ISIN · IT0005487670 LEI · 815600ABEDB6F0BDDE28 XMIL Wholesale and retail trade
Open in API
Filings indexed 188 across all filing types
Latest filing 2022-07-22 Report Publication Anno…
Country IT Italy
Listing XMIL ZJ1

About Farmacosmo

https://www.farmacosmo.com/

Farmacosmo is an e-commerce company that operates an online platform for health, beauty, and personal care products. The company's core business is the online sale of a broad range of items, including parapharmaceuticals, supplements, cosmetics, personal care products, baby supplies, and pet care essentials. Managing its platform in-house, Farmacosmo offers a catalog of over 80,000 products from various brands. The company aims to provide a comprehensive wellness destination by combining the offerings of a pharmacy and a cosmetics retailer, supported by expert advice from professionals.

Recent filings

Filing Released Lang Actions
Farmacosmo Pubblicazione Documento Informativo
Report Publication Announcement Classification · 98% confidence The document is a formal announcement from Farmacosmo S.p.A. dated July 22, 2022, titled "PUBBLICAZIONE DOCUMENTO INFORMATIVO RELATIVO AD UN'OPERAZIONE DI MAGGIORE RILEVANZA CON PARTE CORRELATA" (Publication of Information Document relating to a Major Related Party Transaction). The core message is that the 'Documento Informativo' (Information Document) is now available and directs the reader to where it can be found (company website, Borsa Italiana website). The document itself is very short and primarily serves to announce the availability of another, more substantial document, rather than containing the full details of the transaction or the report itself. According to Rule #2 (The 'MENU VS MEAL' Rule), when a document announces the publication of another report and is brief, it should be classified as a Report Publication Announcement (RPA). The document mentions ESG and sustainability report publication briefly in the company description section, but the primary purpose of this specific filing is the announcement of the Related Party Transaction Document.
2022-07-22 Italian
Farmacosmo Comunicazione Di Variazione Del Capitale Sociale
Share Issue/Capital Change Classification · 98% confidence The document is an official communication from Farmacosmo S.p.A. titled 'COMUNICAZIONE DI VARIAZIONE DEL CAPITALE SOCIALE' (Communication of Variation of Share Capital). The content details the issuance of new ordinary shares following the exercise of warrants, resulting in a change to the total number of shares and the total share capital amount. This directly relates to changes in the company's capital structure. Based on the definitions, the most appropriate classification is 'Capital/Financing Update' (CAP). Although it involves shares, it is a notification of a capital structure change resulting from financing instruments (warrants), rather than a general share repurchase (POS) or a general share issue announcement (SHA). Since the document is a formal press release/regulated information (Informazione Regolamentata) detailing a specific capital event, CAP is the best fit.
2022-07-18 Italian
Farmacosmo Risultati Esercizio Warrant Short-Run E Approvazione Procedura OPC
Share Issue/Capital Change Classification · 99% confidence The document is a formal communication from Farmacosmo S.p.A. dated July 1, 2022, originating from Euronext Growth Milan. The subject ('Oggetto') explicitly mentions 'Farmacosmo Risultati Esercizio Warrant Short-Run E Approvazione Procedura OPC' (Results of Warrant Exercise and Approval of Related Party Procedure). The content details the conclusion of the exercise period for 'WARRANT SHORT-RUN FARMACOSMO 2022', the number of shares issued, and the approval of a new Related Party Procedure. This is a specific corporate action announcement regarding capital structure (warrant exercise resulting in new shares) and governance updates (OPC procedure). While the warrant exercise relates to capital, the document is structured as a press release/regulated information release ('Informazione Regolamentata') announcing specific, non-periodic events. It is not a full Annual Report (10-K), an Interim Report (IR), or a standard Earnings Release (ER). Since it announces the outcome of a financing/capital event (warrant exercise) and a governance update, it fits best under Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if no other category is precise. Given the focus on the issuance of new shares following warrant exercise, CAP is highly relevant. However, the document also mentions the approval of a new governance procedure and is filed as 'REGEM' (Regulated Information). Because the primary financial impact detailed is the issuance of shares following warrant exercise, CAP is the most specific fit among the provided options for the core event described, although RNS is a strong secondary candidate for general regulated news.
2022-07-01 Italian
FARMACOSMO ENTRA NEL SETTORE DELLA TELEMEDICINA - SIGLATA PARTNERSHIP IN ESCLUSIVA COL PORTALE YOUHEALTHY
Regulatory Filings Classification · 95% confidence The document is structured as a 'COMUNICATO STAMPA' (Press Release) dated June 30, 2022, announcing a strategic partnership between Farmacosmo and YouHealthy to enter the telemedicine sector. It details the business implications, quotes the CEO, and provides company background. The metadata indicates it was received as 'REGEM' (Regulated Information) on Euronext Growth Milan. This type of announcement, which is a formal communication about a significant business development (partnership, strategy update), is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to financial results, but since it's a strategic business update, RNS is the most appropriate general regulatory category for non-standard reports. It is not a full 10-K, AR, IR, or a specific proxy/dividend notice. Given the context of a press release announcing a strategic move, RNS (Regulatory Filings) is the best fit as a broad regulatory announcement category.
2022-06-30 Italian
Farmacosmo Nominato Nuovo Investor Relations Manager
Board/Management Information Classification · 98% confidence The document is a press release (COMUNICATO STAMPA) dated June 21, 2022, announcing that Farmacosmo has appointed Paolo Cimmino as the new Investor Relations Manager, replacing the CEO in that role to allow the CEO to focus on growth. This announcement concerns a change in senior personnel responsible for investor communication. This aligns directly with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management. Although it involves an IR role, the core event is a management structure change, not just a general regulatory filing or an earnings release.
2022-06-21 Italian
Farmacosmo Informativa Settimanale Acquisto Azioni Proprie
Transaction in Own Shares Classification · 99% confidence The document is titled 'Farmacosmo Informativa Settimanale Acquisto Azioni Proprie' (Farmacosmo Weekly Information Share Purchase) and details the number of own shares purchased between specific dates (13/06/2022 and 14/06/2022). This explicitly reports on the company's transaction in its own shares (share repurchase). This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS). Although it is a weekly report, the core subject is the repurchase activity, making POS more specific than a general Regulatory Filing (RNS) or a general Capital Update (CAP). The document is a formal communication (Comunicato Stampa) detailing the transaction, not just an announcement that a report is forthcoming.
2022-06-17 Italian

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.